Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PerCellVac2 in recurrent glioblastoma
NCT02808364Phase 1Completed
- Sponsor
- Guangdong Sanjiu Brain Hospital
- Start
- Mar 2016
- Primary completion
- Oct 2017
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in glioblastoma (GBM), sponsored by Guangdong Sanjiu Brain Hospital. Primary endpoint: Incidence of treatment-emergent adverse events and severe adverse events at 3 years. Started Mar 2016; status: completed.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02808364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808364.